Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.

Gregory Riely, MD, is a medical oncologist in the Department of Medicine at Memorial Sloan Kettering Cancer Center. Shirish Gadgeel, MD, is the co-leader of the Thoracic Oncology Research Program and a Mary Lou Kennedy Research Professor at the University of Michigan.

Riely and Gadgeel explain their monitoring habits for cardiac-related toxicities with EGFR TKIs. Baseline EKG and echocardiograms are necessary, as are intermittent echocardiograms when patients are on treatment.

As more data become available for patients being treated with the EGFR TKI mobocertinib (Exkivity), it is expected that the overall understanding of cardiac toxicities will be refined. Moreover, patient education is vital for them to understand their symptoms and management options for cardiac toxicities.

Videos

Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs

Gregory Riely, MD, Medical Oncologist, Vice Chair, Clinical Trials Office, Department of Medicine, Memorial Sloan Kettering, discusses the benefits and challenges of using next-generation sequencing to identify mutations in lung cancer.

With so many mutations now identified in lung cancer, including EGFR, KRAS, BRAF, ALK, and ROS1, it can be difficult to have enough tissue available to test for all of them, says Riely. This means that key tests are not able to be done using standard testing methods.

Next-generation sequencing allows hundreds of genes to be tested for using a very small biopsy specimen.

However, the large volume or results next-generations sequencing provides, can be challenging to understand and utilize, says Riely. Pathologists and oncologists should focus their efforts on only the most common or well-understood mutations in order to make next-generation sequencing an effective tool, he adds.

Gregory Riely, MD Medical Oncologist, Vice Chair, Clinical Trials Office, Department of Medicine, Memorial Sloan Kettering, discusses the benefits and challenges of using next-generation sequencing to identify mutations in lung cancer.

Gregory Riely, MD

Articles

Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs

Dr. Gregory Riely on Using Next-Generation Sequencing to Identify Lung Cancer Mutations